Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Intervention in Spastic Paraplegia SPG5
NCT02314208Phase 2Completed
- Sponsor
- Inserm
- Start
- Jan 2015
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hereditary spastic paraplegia type 5 (SPG5) comparing Xenbilox, Resveratrol and Tahor (3 arms). Primary endpoint: Change of 27-hydroxycholesterol blood level at 2 months. Started Jan 2015; status: completed.
02
Drugs
chenodeoxycholic acidatorvastatinresveratrol
03
Conditions
hereditary spastic paraplegia type 5 (SPG5)
Beyond the preview
Go deeper on NCT02314208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314208.